Basal cell carcinoma market set for expansion as new therapies advance

The basal cell carcinoma market is expected to expand over the next decade as rising diagnoses, aging populations and increased UV exposure lift demand. DelveInsight estimates the global market at several billion dollars, with forecasts ranging from about $3 billion to more than $6 billion in 2024.

Growth is supported by wider uptake of topical therapies, photodynamic approaches and systemic drugs. The USA remains the largest market, reflecting high diagnosis rates, more than 3.6 million cases each year, and established access to advanced medicines such as hedgehog pathway inhibitors and immunotherapy.

However, current systemic options such as Erivedge (vismodegib) from Swiss pharma Roche (ROG: SIX), Odomzo (sonidegib) from Swiss pharma Novartis (NOVN: VX) and Libtayo (cemiplimab) from Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma Sanofi (Euronext: SAN) have notable tolerability limitations. High discontinuation rates leave room for better-tolerated alternatives.